- $2.73bn
- $2.50bn
- $4.09m
Atai Life Sciences jumps as depression drug meets trial goal
Brief: atai Life Sciences And Beckley Psytech To Combine Creating A Global Leader In Psychedelic Mental Health Therapies
Atai Life Sciences climbs on $390 mln Beckley Psytech merger deal
Brief: Atai Life Sciences Reports First Quarter 2025 Financial Results
Brief: Atai Life Sciences Announces First Patient Dosed In Phase 2 Study Of Emp-01 For The Treatment Of Social Anxiety Disorder
Brief: Atai Life Sciences Announces First Patient Dosed In Elumina, The Phase 2 Clinical Trial Of VLS-01 For Treatment-Resistant Depression
Brief: atai Life Sciences Says Pricing Of Registered Underwritten Offering Of 26.1 Million Common Shares At $2.10 Per Share
Brief: Atai Life Sciences Announces Proposed Public Offering Of Common Shares
Atai Life Sciences tumbles on planned stock sale
Atai Life Sciences rises on mid-stage data for alcohol use disorder therapy
U.S. STOCKS ON THE MOVE-Exxon, Chevron, News Corp, Valneva
U.S. STOCKS ON THE MOVE-Expion360, Atai Life Sciences, Intercept Pharmaceuticals
U.S. STOCKS ON THE MOVE-Roblox, CMC Materials, Eli Lilly, energy stocks
U.S. STOCKS ON THE MOVE-Eli Lilly, Aspen Group, Nucor, Galera Therapeutics
Compass Pathways rises as Peter Thiel-backed Atai ups stake
U.S. RESEARCH ROUNDUP-Coresite Realty, Hanmi Financial, Y-Mabs Therapeutics
U.S. STOCKS ON THE MOVE-Anaplan, Nio, Corteva, copper miners
ATAI Life Sciences jumps after Jefferies starts coverage with 'buy'
Psychedelics startup Atai rises as Wall Street psyched about drug portfolio